高级检索

4-苯基-吡咯并[2,3-d]嘧啶类JAK2激酶抑制剂的设计、合成和抗肿瘤活性

刘晓飞, 王庭芳, 鞠曹云, 张灿

刘晓飞, 王庭芳, 鞠曹云, 张灿. 4-苯基-吡咯并[2,3-d]嘧啶类JAK2激酶抑制剂的设计、合成和抗肿瘤活性[J]. 中国药科大学学报, 2017, 48(2): 150-156. DOI: 10.11665/j.issn.1000-5048.20170204
引用本文: 刘晓飞, 王庭芳, 鞠曹云, 张灿. 4-苯基-吡咯并[2,3-d]嘧啶类JAK2激酶抑制剂的设计、合成和抗肿瘤活性[J]. 中国药科大学学报, 2017, 48(2): 150-156. DOI: 10.11665/j.issn.1000-5048.20170204
LIU Xiaofei, WANG Tingfang, JU Caoyun, ZHANG Can. Synthesis and JAK2 inhibitory activities of 4-phenyl-pyrrolo[2, 3-d]pyrimidine derivatives[J]. Journal of China Pharmaceutical University, 2017, 48(2): 150-156. DOI: 10.11665/j.issn.1000-5048.20170204
Citation: LIU Xiaofei, WANG Tingfang, JU Caoyun, ZHANG Can. Synthesis and JAK2 inhibitory activities of 4-phenyl-pyrrolo[2, 3-d]pyrimidine derivatives[J]. Journal of China Pharmaceutical University, 2017, 48(2): 150-156. DOI: 10.11665/j.issn.1000-5048.20170204

4-苯基-吡咯并[2,3-d]嘧啶类JAK2激酶抑制剂的设计、合成和抗肿瘤活性

基金项目: 国家自然科学基金资助项目(No.81503003)

Synthesis and JAK2 inhibitory activities of 4-phenyl-pyrrolo[2, 3-d]pyrimidine derivatives

  • 摘要: 以JAK2激酶抑制剂鲁索替尼(ruxolitinib)为先导化合物,应用分子杂交的药物设计原理,通过结构修饰改造,设计、合成了一系列新的4-苯基-吡咯并[2,3-d]嘧啶类衍生物并进行初步的体外活性评价。以4,6-二羟基嘧啶为起始原料,依次通过Vilsmeier-Haack反应、SNAr取代、成环、脱水、Suzuki偶联、酰基化等多步反应最终合成得到12个目标化合物( 12a ~ 12l ),其结构经1H NMR、13C NMR、HRMS确证。对目标化合物进行体外JAK2激酶活性、GM-CSF诱导的TF-1细胞活性测试,结果表明,部分化合物( 12b12e12h )具有一定程度的JAK2抑制活性;采用MTT法测试目标化合物对JAK2非依赖性A549细胞的抗增殖能力,结果显示,该类化合物A549细胞表现出良好的增殖抑制活性,尤其是化合物 12c (IC50=0.12 μmol/L)活性最强,表明该类化合物具有潜在的研究开发价值。
    Abstract: A series of 4-phenyl-pyrrolo[2, 3-d]pyrimidine derivatives were synthesized through modifying the structure of the lead compound ruxolitinib by molecular hybridization strategy. It was synthesized from pyrimidine-4, 6-diol by Vilsmeier-Haack reaction, SNAr reaction, cyclized, dehydration, Suzuki coupling and finally acylated to give 12 new compounds( 12a - 12l ). All structures of the synthesized compounds were confirmed by 1H NMR, 13C NMR, and HRMS analysis. The biological activities were evaluated in vitro. Their JAK2 inhibitory activities were studied using JAK2 enzymatic and TF1-GMCSF cellular assays. The results indicated that compounds 12b , 12e and 12h showed moderate activity. The anti-tumor activities were studied against JAK2-independent A549 cell line by the MTT assay. Results showed that the title compounds exhibited potent antiproliferative effect on A549, especially compound 12c (IC50=0. 12 μmol/L), suggesting that this series compounds might be promising anti-tumor agents for futher investigation.
  • [1] Levine RL,Wadleigh M,Cools J,et al.Activating mutation in the tyrosine kinase JAK2 in polycythemia vera,essential thrombocythemia,and myeloid metaplasia with myelofibrosis[J].Cancer Cell,2005,7(4):387-397.
    [2] Kralovics R, Passamont F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders[J].N Engl J Med,2005,352(17):1779-1790.
    [3] Ma W,Zhang X,Wang X,et al.MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders[J].Diagn Mol Pathol,2011,20(1):34-39.
    [4] Baxter EJ,Scott LM,Campbell PJ,et al.Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders[J].Lancet,2005,365(9464):1054-1061.
    [5] James C,Ugo V,Lecoueédic JP,et al.A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera[J].Nature,2005,434(7037):1144-1148.
    [6] Rosenthal A,Mesa RA.Janus kinase inhibitors for the treatment of myeloproliferative neoplasms[J].Exp Opin Pharmacother,2014,15(9):1265-1276.
    [7] Santos FP, Verstovsek S. Clinic JAK2 inhibitors: are they the solution[J]?Cl Lymph Myelom Leuk,2011,11(Suppl 1):s28-36.
    [8] Schenkel LB,Huang X,Cheng A,et al.Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors[J].J Med Chem,2011,54(24):8440-8450.
    [9] Changelian PS,Flanagan ME,Ball DJ,et al.Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor[J].Science,2003,302(5646):875-878.
    [10] Ning CQ,Lu C,Hu L,et al.Macrocyclic compounds as anti-cancer agents:design and synthesis of multi-acting inhibitors against HDAC,FLT3 and JAK2[J].Eur J Med Chem,2015,95:104-115.
    [11] Hanan EJ,Van AA,Barrett K,et al.Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors[J].J Med Chem,2012,55(22):10090-10107.
    [12] Zimmermann K,Sang X,Mastalerz HA,et al.9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors[J].Bioorg Med Chem Lett,2015,25(14):2809-2812.
    [13] Zhang C,Lv F,Zhou L,et al.Effect of verapamil on the expression of EGFR and NM23 in A549 human lung cancer cells[J].Anticancer Res,2009,29(1):27-32.
计量
  • 文章访问数:  1036
  • HTML全文浏览量:  1
  • PDF下载量:  1544
  • 被引次数: 0
出版历程
  • 刊出日期:  2017-04-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭